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Abstract
Background: Sequence type 72 methicillin-resistant Staphylococcus aureus (MRSA) SCCmec type IV (ST72-MRSA-IV)
is the most common community-acquired MRSA clone in Korea. Resistance to daptomycin or vancomycin among
community-acquired MRSA clones is not well described in the literature. We herein report the first case of
vancomycin-intermediate, daptomycin-nonsusceptible ST72-MRSA-IV.
Case presentation: A 45-year-old Japanese man underwent aortic arch prosthesis implantation for treatment of a
dissecting aortic aneurysm. Fourteen months later, he developed a prosthetic graft infection of the aortic arch and
an anterior mediastinal abscess caused by ST72-MRSA-IV. First-line treatment with vancomycin and rifampicin failed,
and daptomycin was thus administered. After several days, the treatment was changed to linezolid because of the
re-emergence of fever. The patient’s condition resolved and no recurrence or other problems were seen for 1 year
post-treatment. The infectious agent was definitively identified as vancomycin-intermediate, daptomycin-nonsusceptible,
rifampicin-resistant ST72-MRSA-IV based on culture results and minimum inhibitory concentration testing.
Conclusion: This case report illustrates the importance of fully understanding the changing epidemiology of infectious
agents and the risk factors for the development of antibiotic resistance. Such information will help to minimize the
emergence and spread of antibiotic-resistant strains. This report concerns one particular bacterial strain; however, the
basic concepts involved in this case translate to all infectious disease fields.
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Background
Community-acquired methicillin-resistant Staphylococcus
aureus (CA-MRSA) was first reported in 1981 in patients
with MRSA infections without general healthcare-associ-
ated risk factors. The incidence of CA-MRSA infection
has continually increased since the mid-1990s [1]. The
features of CA-MRSA strains differ from those of health-
care-associated MRSA (HA-MRSA) strains. Reported
differences between infections with these two strains
include genetic traits, clinical features, patient groups,
infection routes, recommended treatments and manage-
ment, prevention procedures, and antimicrobial suscepti-
bility patterns [2]. In recent years, however, these strains
have been frequently observed in healthcare settings and
have been shown to cause both community-onset health-
care-associated infections and nosocomial infections [1,3].
CA-MRSA clones vary among geographic settings.
Sequence type 8 (ST8)-staphylococcal cassette chromo-
some mec (SCCmec) type IV (ST8-MRSA-IV, known as
USA300) is the most common and epidemic CA-MRSA
clone in North America [4]. The most predominant
CA-MRSA clones in Asian countries include ST59-
MRSA-IV in Taiwan, Hong Kong, Vietnam, and Sri
Lanka; ST30-MRSA-IV in the Philippines; and ST72-
MRSA-IV in Korea. Clinical strains of ST72-MRSA-IV
are mostly limited to Korea and lack Panton–Valentine
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leukocidin (PVL) genes. ST72-MRSA-IV isolates usually
have very low resistance to most non-β-lactam agents,
which is a typical characteristic of CA-MRSA isolates
containing SCCmec type IV elements [5]. Multidrug resist-
ance in ST72-MRSA-IV isolates has rarely been reported
[6,7]. ST72-MRSA-IV strains, like other CA-MRSA strains,
commonly cause skin and soft tissue infections or pneu-
monia and have sometimes been associated with serious
or fatal diseases such as severe sepsis, septic shock, and
surgical site infection [8].
Daptomycin was first approved in 2003 for the treatment
of complicated Gram-positive skin and skin structure
infections. It is a novel lipopeptide antibiotic with a unique
mechanism of action against Gram-positive bacteria,
binding to bacterial membranes and causing rapid
depolarization of the membrane potential [9]. Because
daptomycin was confirmed to be effective against strains
that were resistant to existing antibiotics, its clinical
application has been increasing as the first-line therapy
for bacteremia, surgical site infection, and right-sided
infective endocarditis [10]. With the exception of USA300,
resistance to daptomycin or vancomycin among CA-
MRSA clones has not been well described [11,12]. The
first case of an ST72-MRSA-IV strain in Asia demon-
strating vancomycin-intermediate resistance was reported
in 2012 by Chung et al. in Korea [13]. To our knowledge,
the present case is the first report of an ST72-MRSA-IV




A 45-year-old Japanese man presented to the emergency
department with the main complaints of fever and disturb-
ance of consciousness (Glasgow Coma Score of E3V4M6).
He had a previous medical history of dissecting aortic
aneurysm (Stanford type A), for which he underwent
transverse aortic arch replacement 14 months before
admission. He had no history of travelling abroad or
having his skin pierced. He had previously been treated
with vancomycin at 3 g/day (1 g intravenously [IV] three
times a day [TID]) and rifampicin at 600 mg/day (300 mg
orally [PO] twice a day [BID]) for 2 days before being
transferred to our hospital.
The patient’s condition was diagnosed as an anterior
mediastinal abscess and hemorrhagic cerebral infarction
associated with a prosthetic graft infection of the aortic
arch. Surgical intervention to remove the infected graft,
which required anticoagulant therapy during cardiopul-
monary bypass, was not possible because of intracerebral
hemorrhage. Initial treatment for the prosthetic graft infec-
tion was started with vancomycin at 3 g/day (1 g IV TID)
and cefazolin at 6 g/day (2 g IV TID). On the second
hospital day, drainage and continuous irrigation were
started for treatment of the anterior mediastinal abscess.
Because the results of the blood culture performed 2 days
before admission revealed an MRSA infection, the treat-
ment was switched to vancomycin at 3 g/day (1 g IV TID)
and rifampicin at 600 mg/day (300 mg PO BID); this
treatment was continued for 9 days. The isolates from
the blood and anterior mediastinal cultures performed
on the day of admission also indicated MRSA infec-
tion. The vancomycin serum trough levels remained at
9.8–12.2 μg/ml during vancomycin treatment. The vanco-
mycin minimum inhibitory concentration (MIC) of the
MRSA strain isolated from the pus in the abscess was
2 μg/ml, and this strain was also susceptible to most
non-β-lactam agents except gentamicin (Table 1). The
blood culture became negative for MRSA during the
course of vancomycin and rifampicin therapy. However,
the patient became feverish again on the 10th hospital
day, and the treatment was switched to IV daptomycin
at 6 mg/kg/day and rifampicin. On the 40th day, after
the patient had remained in a stable condition for several
days with daptomycin and rifampicin treatment, his fever
returned and the blood culture became positive again
for MRSA. Therefore, we suspected nonsusceptibility to
daptomycin. Daptomycin was discontinued and treatment
with linezolid was initiated at 1200 mg/day (600 mg IV
BID). Reconstruction of the acute aortic dissection was
carried out on the 61st day because the chest computed
tomography scan performed during therapy showed
persistence of the anterior mediastinal abscess and gal-
lium scintigraphy showed persistence of prosthetic
graft-associated inflammation. The infected prosthetic
graft was completely removed and replaced. After the
surgery, antimicrobial treatment was switched to linez-
olid at 1200 mg/day (600 mg PO BID) and clindamycin
Table 1 Susceptibility of MRSA to various antimicrobial




Isolate 1 Isolate 1’ Isolate 2 Isolate 3 Isolate 4
Oxacillin >4 [R] >4 [R] >4 [R] >4 [R] >4 [R]
Gentamicin 8 [R] >8 [R] 8 [R] >8 [R] >8 [R]
Erythromycin <0.25 [S] <0.25 [S] <0.25 [S] <0.25 [S] <0.25 [S]
Clindamycin <0.5 [S] <0.5 [S] <0.5 [S] <0.5 [S] <0.5 [S]
Minocycline <2 [S] <2 [S] <2 [S] <2 [S] <2 [S]
Teicoplanin <2 [S] <2 [S] <2 [S] 4 [S] 4 [S]
Vancomycin 1 [S] 2 [S] 1 [S] 2 [S] 4 [I]
Levofloxacin <0.5 [S] <0.5 [S] <0.5 [S] <0.5 [S] <0.5 [S]
Rifampicin <1 [S] <1 [S] >2 [R] >2 [R] >2 [R]
Susceptibilities to the agents in Table 1 were evaluated by broth microdilution
(MicroScan; Siemens, Tokyo, Japan).
Isolate 1: blood culture on the first hospital day; Isolate1’: pus from the abscess
on the first hospital day; Isolate 2: pus from the abscess on the sixth hospital
day; Isolate 3: blood culture on the 40th hospital day; Isolate 4: pus from the
abscess on the 55th hospital day. S: Susceptible; I: Intermediate; R: Resistant.
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at 1800 mg/day (600 mg PO TID). The patient’s condition
subsequently improved, and recurrence was not observed
for 12 months of follow-up. The time course of his body
temperature variations and antibiotic treatment regimen
are shown in Figure 1.
Methods and results
Antimicrobial susceptibility testing was performed accord-
ing to the Clinical and Laboratory Standards Institute
(CLSI) guidelines (Tables 1 and 2). Rifampicin susceptibil-
ity testing, not routinely included, was performed after the
treatment and revealed resistance at an MIC of >2 μg/ml
from Isolate 2 in the course of vancomycin and rifampicin
dosing (Table 1). The MRSA isolate from the pus in the
abscess on the 55th hospital day (Isolate 4) demonstrated
a vancomycin MIC of 4 μg/ml, indicating vancomycin-
intermediate S. aureus (VISA) (Table 1). The daptomycin
MICs of the MRSA isolates obtained from the blood
and anterior mediastinal abscess cultures were evalu-
ated by the broth microdilution method, using Micro-
Scan (Siemens, Tokyo, Japan) and frozen plate (Eiken
Chemical Co., Ltd., Tokyo, Japan), and Etest® (bioMérieux,
Marcy-l'Étoile, France). The MRSA isolates showed sus-
ceptibility to daptomycin at the time of admission, with
MICs of ≤0.5 μg/ml, 0.5, and 0.125 μg/ml upon analysis
by MicroScan, frozen plate, and Etest®, respectively. Over
time, however, these MICs increased to >1, 1.5, and
1.5 μg/ml, respectively, indicating daptomycin nonsus-
ceptibility (Table 2). The interpretations of the MIC
results (susceptible, intermediate, nonsusceptible, or
resistant) were determined according to the CLSI
guidelines. MRSA isolates with daptomycin MICs
of >1 μg/ml, vancomycin MICs of 4 to 8 μg/ml, and ri-
fampicin MICs of >2 μg/ml were defined as daptomycin
nonsusceptible, vancomycin-intermediate resistant, and
rifampicin resistant, respectively.
Pulsed-field gel electrophoresis was performed using a
contour-clamped homogeneous electric field dynamic
regulation III system (CHEF-DR system; Bio-Rad Labora-
tories, Hercules, CA, USA) as previously described by
McDougal et al. [14]. The results indicated that the
isolates obtained sequentially in this case were derived
from the same origin. Multilocus sequence typing (MLST)
analysis was performed by sequencing seven housekeeping
genes (arcC, aroE, glpF, gmk, pta, tpi, and yqiL) based on
the MLST database (http://saureus.mlst.net), as described
by Enright et al. [15]. The characterization of SCCmec
[16] and the detection of PVL genes [17] were performed
by polymerase chain reaction as described previously.
Typing of the MRSA isolates revealed that they belonged
to ST72 (1-4-1-8-4-4-3), carried SCCmec type IV, and
were negative for PVL.
Figure 1 Time course of body temperature variation and antibiotic regimen of the patient. The patient’s blood culture became negative
for MRSA once in the course of vancomycin therapy, but his fever persisted. With the initiation of daptomycin therapy, his temperature remained
relatively low for several days and then increased when the blood culture became positive again for MRSA. 1: blood culture on the first hospital day; 1’:
pus from the abscess on the first hospital day; 2: pus from the abscess on the 6th hospital day; 3: blood culture on the 40th hospital day; 4: pus from
the abscess on the 55th hospital day. CEZ: cefazolin; VCM: vancomycin; RFP: rifampicin; DAP: daptomycin; LZD: linezolid; CLDM: clindamycin
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Discussion
The antimicrobial susceptibility rates of 25 different ST72
isolates in Korea were previously reported as follows:
erythromycin (4%), clindamycin (4%), ciprofloxacin (60%),
TMP/SXT (96%), gentamicin (72%), rifampicin (92%), and
vancomycin (100%) [6]. Although the ST72-MRSA-IV
isolates in the present case were susceptible to most
non-β-lactam agents (Table 1), they developed reduced
susceptibility to three key drugs, namely vancomycin,
daptomycin, and rifampicin.
The possible risk factors for the development of dapto-
mycin nonsusceptible strains in our case, as in common
MRSA strains, included the following: the presence of an
intractable infectious disease (prosthetic graft infection of
the aortic arch), a delay in the performance of necessary
surgical care [18], previous exposure to vancomycin or
a vancomycin MIC of ≥2 μg/ml [19], treatment with in-
sufficient doses of daptomycin [20], and prolonged use
of daptomycin [21]. Additionally, some reports have stated
that VISA exhibits reduced susceptibility to daptomycin
[22,23].
Another possible factor was the presence of resistance
to rifampicin, which was added to allow for vancomycin
penetration into the biofilm [24]. The combined use of
vancomycin and rifampicin is reportedly a potential risk
factor in the treatment of MRSA [25]. Cui et al. con-
firmed that rpoB (RNA polymerase subunit β) mutation,
known to be associated with rifampicin resistance [26],
conferred dual heteroresistance to daptomycin and vanco-
mycin in S. aureus and exhibited a thickened cell wall and
reduction of the negative charge on the cell surface [27].
The mechanism of resistance to daptomycin remains un-
clear. However, considering that the present case involved
a daptomycin-nonsusceptible VISA strain with rifampicin
resistance, it is quite possible that the rpoB mutation, led
by the combined treatment of vancomycin and rifampicin,
may have contributed to the development of resistance.
Among the above-mentioned risk factors, our case
involved those that could have been avoided or decreased
by alternative therapy. An alternative approach to decreas-
ing these risk factors could have been the administration
of high-dose daptomycin upon the diagnosis of an intract-
able MRSA infection. Daptomycin exhibits rapid and
concentration-dependent bactericidal activity, which tran-
slates into an increased rate of killing against most drug-
susceptible strains and improved activity even against
some nonsusceptible strains [20,28,29]. Rose et al. stated
that high-dose daptomycin at 10 mg/kg/day was likely to
prevent the emergence of increased daptomycin MICs
[20,29]. The safety and efficacy of daptomycin at 8 to
12 mg/kg/day for the treatment of complicated bacteremia
have also been reported [28]. Additionally, early use of
daptomycin at higher doses was proven to be effective
when the initial vancomycin MIC showed susceptibility
at >1 μg/ml [30]. Although the Infectious Diseases Society
of America recommends an alternative to vancomycin
for isolates with a vancomycin MIC of ≥2 μg/ml, we
recommend an early treatment switch in patients with
intractable disease with a vancomycin susceptibility level
of >1 μg/ml.
Conclusions
We have herein reported the first case of daptomycin
nonsusceptibility among clinical ST72-MRSA-IV strains,
which are rarely observed in countries other than Korea.
In this case, failure to implement the appropriate dose
and combination of antibacterial agents might have con-
tributed to the development of nonsusceptibility. Further
efforts to understand the changing epidemiology and the
risk factors for antibiotic resistance will be necessary to
minimize the future emergence or spread of antibiotic-
resistant strains.
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MRSA: Methicillin-resistant Staphylococcus aureus; CA: Community-acquired;
SCCmec: Staphylococcal cassette chromosome mec; ST72-MRSA-IV: Sequence
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Table 2 Susceptibility of MRSA to daptomycin as analyzed by clinical laboratory testing
Method Daptomycin MIC (μg/ml) [interpretation]
Isolate 1 Isolate 1’ Isolate 2 Isolate 3 Isolate 4
MicroScan (Siemens, Tokyo, Japan) ≤0.5 [S] ≤0.5 [S] ≤0.5 [S] >1 [NS] >1 [NS]
Frozen plate (Eiken, Tokyo, Japan) 0.5 [S] 0.5 [S] 0.25 [S] 1 [S] 1.5 [NS]
Etest® (bioMérieux, Marcy-l'Étoile, France) 0.125 [S] 0.125 [S] 0.125 [S] 1 [S] 1.5 [NS]
Isolate 1: blood culture on the first hospital day; Isolate1’: pus from the abscess on the first hospital day; Isolate 2: pus from the abscess on the sixth hospital day;
Isolate 3: blood culture on the 40th hospital day; Isolate 4: pus from the abscess on the 55th hospital day. S: Susceptible; NS: Nonsusceptible.
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